Home  |  Contact

Cellosaurus SK-MEL-28-VR (CVCL_AP99)

Cell line name SK-MEL-28-VR
Accession CVCL_AP99
Resource Identification Initiative To cite this cell line use: SK-MEL-28-VR (RRID:CVCL_AP99)
Comments Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
Sequence variations Homozygous for BRAF p.Val600Glu (c.1799T>A) (from parent cell line).
Heterozygous for CDK4 p.Arg24Cys (c.70C>T) (from parent cell line).
Homozygous for EGFR p.Pro753Ser (c.2257C>T) (from parent cell line).
PTEN p.Thr167Ala (c.499A>G) (from parent cell line).
Homozygous for TP53 p.Leu145Arg (c.434T>G) (from parent cell line).
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0526 (SK-MEL-28)
Sex of cell Male
Age at sampling 51Y
Category Cancer cell line

PubMed=26497853; DOI=10.18632/oncotarget.5755
Fofaria N.M., Frederick D.T., Sullivan R.J., Flaherty K.T., Srivastava S.K.
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Oncotarget 6:40535-40556(2015)

Other Wikidata; Q54954017